论文部分内容阅读
卵巢癌是妇科恶性肿瘤患者死亡的首要原因。正确的外科步骤有助于选择最适当的治疗和适度的细胞减灭,增加以后治疗成功的可能性。因此术前需要可靠的无损伤性的试验以确定病人是否患有卵巢癌。本文测定100例盆腔肿块妇女术前血清中的肿瘤相关抗原:CA125、TAG72和CA15-3。CA125这种肿瘤相关抗原被大多数卵巢上皮癌表达。用放免测定法测定大约80%卵巢上皮癌患者血清中CA125升高。非浸润性妇科肿瘤和一些非妇科的恶性肿瘤患者,血清CA125也有升高。健康人血清中CA125常不升高。应用多种肿瘤相关抗原联合测定可以改进单独用CA125时得到的特异性。肿瘤相关糖蛋白(TAG72)抗原能根据B72.3单克隆抗体用
Ovarian cancer is the leading cause of death in patients with gynecological malignancies. Correct surgical procedures help select the most appropriate treatment and moderate cytoreduction, increasing the chances of successful treatment later on. Therefore, preoperative reliable non-invasive test to determine whether the patient has ovarian cancer. In this paper, 100 patients with pelvic masses of preoperative serum tumor-associated antigens: CA125, TAG72 and CA15-3. CA125 This tumor-associated antigen is expressed in most epithelial ovarian cancers. Radioimmunoassay was used to measure elevated serum CA125 levels in approximately 80% of patients with epithelial ovarian cancer. Non-invasive gynecological cancer and some non-gynecological malignancies, serum CA125 also increased. CA125 in healthy human serum often does not increase. The combination of multiple tumor-associated antigens can improve the specificity obtained with CA125 alone. Tumor-associated glycoprotein (TAG72) antigen can be used according to B72.3 monoclonal antibody